Press Release; Berlin, January 8, 2007
MOLOGEN AG to upscale and optimize production of DNA molecule
The Berlin-based biotechnology company MOLOGEN AG announced today that it succeeded to upscale the production of its dSLIM® molecule significantly. The production volume has been increased by a factor of 25 to gram scale. At the same time, production costs have been decreased by around 75 percent.
This success allows MOLOGEN to produce the necessary volumes of dSLIM® for all future clinical studies in GMP quality. Based on the current experiences, the company expects that a further up-scaling and optimization of the dSLIM® synthesis for commercialization purposes can easily be achieved.
dSLIM® has been developed by MOLOGEN AG. dSLIM® is a DNA-based immunomodulator and TLR 9 agonist. dSLIM® molecules consist of non-coding DNA without any chemical modifications.
MOLOGEN currently develops a dSLIM®-based therapy for the treatment of colon cancer. The results already achieved indicate very good tolerability and an increase of efficacy of standard chemo-therapy.
MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.
Disclaimer concerning prognoses
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.